Spero Therapeutics (SPRO) Competitors $2.33 -0.02 (-0.85%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.33 0.00 (0.00%) As of 07/25/2025 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SPRO vs. DNA, TYRA, PGEN, ARVN, TBPH, SAGE, ORGO, TSHA, ABVX, and BCYCShould you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Ginkgo Bioworks (DNA), Tyra Biosciences (TYRA), Precigen (PGEN), Arvinas (ARVN), Theravance Biopharma (TBPH), Sage Therapeutics (SAGE), Organogenesis (ORGO), Taysha Gene Therapies (TSHA), Abivax (ABVX), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. Spero Therapeutics vs. Its Competitors Ginkgo Bioworks Tyra Biosciences Precigen Arvinas Theravance Biopharma Sage Therapeutics Organogenesis Taysha Gene Therapies Abivax Bicycle Therapeutics Spero Therapeutics (NASDAQ:SPRO) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability. Do insiders & institutionals believe in SPRO or DNA? 25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 5.5% of Spero Therapeutics shares are held by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is SPRO or DNA more profitable? Spero Therapeutics has a net margin of -156.48% compared to Ginkgo Bioworks' net margin of -198.84%. Ginkgo Bioworks' return on equity of -52.35% beat Spero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spero Therapeutics-156.48% -123.50% -58.96% Ginkgo Bioworks -198.84%-52.35%-27.14% Which has preferable earnings & valuation, SPRO or DNA? Spero Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks. Spero Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpero Therapeutics$47.98M2.72-$68.57M-$1.28-1.82Ginkgo Bioworks$237.42M3.44-$547.03M-$9.16-1.52 Does the media prefer SPRO or DNA? In the previous week, Ginkgo Bioworks had 7 more articles in the media than Spero Therapeutics. MarketBeat recorded 8 mentions for Ginkgo Bioworks and 1 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.87 beat Ginkgo Bioworks' score of 0.77 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Spero Therapeutics Very Positive Ginkgo Bioworks Positive Do analysts prefer SPRO or DNA? Spero Therapeutics presently has a consensus price target of $5.00, suggesting a potential upside of 114.59%. Ginkgo Bioworks has a consensus price target of $8.50, suggesting a potential downside of 39.09%. Given Spero Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Spero Therapeutics is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Ginkgo Bioworks 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, SPRO or DNA? Spero Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. SummaryGinkgo Bioworks beats Spero Therapeutics on 9 of the 16 factors compared between the two stocks. Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRO vs. The Competition Export to ExcelMetricSpero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$131.39M$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-1.8221.1828.1020.05Price / Sales2.72288.50432.4490.07Price / CashN/A42.7636.2258.56Price / Book2.748.378.665.87Net Income-$68.57M-$55.19M$3.25B$258.55M7 Day Performance-1.69%5.88%4.23%3.74%1 Month Performance-19.66%17.33%10.52%11.75%1 Year Performance62.37%4.42%34.41%18.03% Spero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPROSpero Therapeutics3.9232 of 5 stars$2.33-0.9%$5.00+114.6%+64.7%$131.39M$47.98M-1.82150Positive NewsDNAGinkgo Bioworks0.6255 of 5 stars$9.91-0.7%$8.50-14.3%N/A$580.29M$237.42M-1.08640News CoverageTYRATyra Biosciences3.1451 of 5 stars$10.91+6.3%$30.83+182.6%-45.7%$579.21MN/A-6.6920PGENPrecigen3.8488 of 5 stars$1.95+6.6%$6.00+207.7%-5.4%$575.60M$4.20M-3.48190Positive NewsARVNArvinas4.031 of 5 stars$7.87+1.0%$20.29+157.8%-73.4%$574.43M$263.40M-11.92420News CoverageUpcoming EarningsTBPHTheravance Biopharma1.6559 of 5 stars$11.47+1.5%$16.60+44.7%+8.0%$573.50M$64.38M-9.72110SAGESage Therapeutics3.4023 of 5 stars$9.15-1.3%$8.75-4.4%-16.0%$572.97M$41.24M-1.58690News CoverageUpcoming EarningsORGOOrganogenesis4.5448 of 5 stars$4.49+4.4%$6.00+33.6%+56.2%$569.56M$482.04M-26.41950TSHATaysha Gene Therapies4.2515 of 5 stars$2.64flat$8.17+209.3%+16.7%$566.70M$8.33M-7.76180ABVXAbivax2.3892 of 5 stars$8.83+6.8%$31.00+251.1%+462.5%$560.44MN/A0.0061Trending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeBCYCBicycle Therapeutics3.8458 of 5 stars$8.08+1.0%$25.00+209.4%-64.4%$559.54M$35.28M-2.57240 Related Companies and Tools Related Companies Ginkgo Bioworks Alternatives Tyra Biosciences Alternatives Precigen Alternatives Arvinas Alternatives Theravance Biopharma Alternatives Sage Therapeutics Alternatives Organogenesis Alternatives Taysha Gene Therapies Alternatives Abivax Alternatives Bicycle Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRO) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
